同种异体富血小板血浆临床应用的研究进展  

Advances in research on the clinical application of allogeneic platelet-rich plasma

作　　者：赵芊 李亚坤 李智[1] Qian Zhao;Yakun Li;Zhi Li(Third Hospital of Shanxi Medical University,Shanxi Bethune Hospital,Taiyuan 030032,China)

机构地区：[1]山西医科大学第三医院、山西白求恩医院医疗美容/烧伤整形科,太原030032

出　　处：《中华损伤与修复杂志（电子版）》2024年第4期364-367,共4页Chinese Journal of Injury Repair and Wound Healing(Electronic Edition)

基　　金：山西省科技厅重点研发项目(201803D31141)。

摘　　要：自体富血小板血浆(au-PRP)是将自体血液离心后提取的血小板浓聚物,具有较强的组织修复和再生能力,在临床中已被广泛应用。但其存在使用禁忌证及相对禁忌证,且年龄或基础疾病等因素影响其使用效果。因此,研究者对同种异体富血小板血浆(al-PRP)展开了相关研究。本文对al-PRP使用可行性和安全性、优点和不足及其在临床中的应用进行综述。Autologous platelet-rich plasma(au-PRP)is a platelet concentrate derived from autologous blood via centrifugation,which has been widely used in clinical practice owing to its pronounced tissue reparative and regenerative properties.However,its application is circumscribed by contraindications and relative contraindications,alongside potential attenuations in efficacy linked to factors such as age and basic diseases.Consequently,researchers have undertaken investigations into allogeneic platelet-rich plasma(al-PRP).This article comprehensively reviewed the feasibility and safety of al-PRP utilization,and the advantages,drawbacks and clinical applications of al-PRP.

关 键 词：同种异体富血小板血浆 慢性难愈性创面 运动系统损伤 

分 类 号：R644[医药卫生—外科学]